Flucytosine primary resistance in Candida species and Cryptococcus neoformans

被引：37

作者：

Cuenca-Estrella M. ^{[1
]}

Díaz-Guerra T.M. ^{[1
]}

Mellado E. ^{[1
]}

Rodríguez-Tudela J.L. ^{[1
]}

机构：

[1] Servicio de Micología, Ctro. Nac. de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda (Madrid)

来源：

European Journal of Clinical Microbiology and Infectious Diseases | 2001年 / 20卷 / 4期

关键词：

Amphotericin; Fluconazole; Candida Albicans; Clinical Isolate; Itraconazole;

D O I：

10.1007/PL00011265

中图分类号：

学科分类号：

摘要：

The in vitro activity of flucytosine (5FC) against 1,140 clinical isolates of Candida spp. and Cryptococcus neoformans was evaluated and compared with the activity of amphotericin B, fluconazole and itraconazole. Overall, 87.72% (1,000/1,140) of yeasts were susceptible to 5FC. This agent showed less potent in vitro activity against Candida glabrata, Candida krusei, Candida guilliermondii and Cryptococcus neoformans (MIC90s, 8-16 mg/ml) and intermediate activity or resistance to 6.5% of Candida albicans, 5.1% of Candida tropicalis and 0.8% of Candida parapsilosis strains. Amphotericin B showed potent activity against isolates with an MIC of 5FC ≥ 8 μg/ml. A total of 112 of 140 strains that were 5FC-intermediate or -resistant showed decreased susceptibility to azoles (P < 0.01).

引用

页码：276 / 279

页数：3

共 15 条

[1] Bennet J.E., Flucytosine, Annals of Internal Medicine, 86, pp. 319-322, (1977)
[2] Kauffman C.A., Carver P.L., Antifungal agents in the 1990s, Drugs, 53, pp. 539-549, (1997)
[3] White T.C., Marr K.A., Bowden R.A., Clinical, cellular, and molecular factors that contribute to antifungal drug resistance, Clinical Microbiology Reviews, 11, pp. 382-402, (1998)
[4] Viviani M.A., Flucytosine - What is its future?, Journal of Antimicrobial Chemotherapy, 35, pp. 241-244, (1995)
[5] Barchiesi F., Arzeni D., Caselli F., Scalise G., Primary resistance to flucytosine among clinical isolates of Candida spp, Journal of Antimicrobial Chemotherapy, 45, pp. 408-409, (2000)
[6] Iwata K., Drug resistance in human pathogenic fungi, European Journal of Epidemiology, 8, pp. 407-421, (1992)
[7] Graybill J.R., The future of antifungal therapy, Clinical Infectious Diseases, 22, SUPPL. 5, pp. 166-178, (1996)
[8] Francis P., Walsh T.A., Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy, Clinical Infectious Diseases, 15, pp. 1003-1018, (1992)
[9] Auger P., Dumas C., Joly J., A study of 666 strains of Candida albicans: Correlation between serotype and susceptibility to 5-fluorocytosine, Journal of Infectious Diseases, 139, pp. 590-594, (1979)
[10] Weber S., Polak A., Susceptibility of yeasts isolates from defined German patient groups to 5-fluorocytosine, Mycoses, 35, pp. 163-171, (1992)

← 1 2 →